Table 1.

Patient and Transplant demographics

	Study group n=46
Sex (male/female)	27/19
Median age (range) at HCT	13.9 (6–23)
Median age (range) at vaccination	14.7 (9.6–25.4)
Diagnosis
Malignancy/bone marrow failure	40
Acute Leukemia	32
MDS/aplastic anemia	5 (3/2)
CML/myeloproliferative disorder	2 (1/1)
Ewing’ sarcoma	1
Non-malignant disease	6
Hemoglobinopathy	4
Combined immunodeficiency disease	1
Hereditary Lymphohistiocytosis	1
Median time (range) from HCT to vaccine	2.34 (0.6–5.2) years
Donor
HLA-identical sibling	17 (37%)
HLA-Mismatched related	6 (13%)
Unrelated	23 (50%)
HCT type
T cell depleted	26 (57%)
T cell depleted HLA-identical sibling	4
T cell depleted HLA-mismatched related	6
T cell depleted Unrelated	16
T-replete	20 (43%)
Unmodified HLA-identical sibling	13
Unmodified Unrelated	2
Unmodified double cord blood	5